Results 61 to 70 of about 345,959 (307)

Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non‐small cell lung cancer

open access: yesThoracic Cancer
Background Circulating tumor DNA (ctDNA) has emerged as a potential novel biomarker to predict molecular residual disease (MRD) in lung cancer after definitive treatment.
Xiaoru Tian   +13 more
doaj   +1 more source

Adjuvant Therapy [PDF]

open access: yesJornal Brasileiro de Nefrologia, 2014
Carlos Eduardo, Poli de Figueiredo   +1 more
openaire   +2 more sources

Clinical Characteristics and Outcomes of Early‐Onset Versus Late‐Onset LGI1‐Antibody Encephalitis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Leucine‐rich glioma‐inactivated 1 antibody (LGI1‐Ab) encephalitis predominantly affected older individuals, but has also been reported in younger patients. However, the demographic, clinical, and prognostic characteristics of early‐onset LGI1‐Ab encephalitis have yet to be systematically elucidated. This study aims to systematically
Yu Kong   +7 more
wiley   +1 more source

Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review

open access: yesTherapeutics and Clinical Risk Management, 2009
Alain MonnierInstitut Régional Fédératif du Cancer (IFRC), Centre Hospitalier Belfort-Montbéliard, Montbéliard, FranceAbstract: Aromatase inhibitors (AIs) are becoming more widely used than tamoxifen
Alain Monnier
doaj  

Review: Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects

open access: yesTherapeutic Advances in Medical Oncology, 2010
Colon cancer represents the second leading cause of cancer-related deaths. For patients who have undergone curative surgery, adjuvant therapy can reduce the risk of recurrence and death from relapsed or metastatic disease. Postoperative chemotherapy with
Diogo Assed Bastos   +3 more
doaj   +1 more source

The MMP‐9/TIMP‐1 Ratio and Concentrations of Osteopontin Are Elevated in Cerebrospinal Fluid of People With Multiple Sclerosis and Decrease After Autologous Hematopoietic Stem Cell Transplantation

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives To evaluate the utility of cerebrospinal fluid (CSF) biomarkers—matrix metalloproteinase‐9 (MMP‐9), tissue inhibitor of metalloproteinases‐1 (TIMP‐1), the MMP‐9/TIMP‐1 ratio, and osteopontin (OPN)—as indicators of blood–brain barrier (BBB) integrity and disease activity in people with relapsing–remitting multiple sclerosis (pwMS ...
Ivan Pavlovic   +6 more
wiley   +1 more source

Basilar Artery Occlusion Stroke Managed With Tenecteplase Versus Alteplase Before Endovascular Treatment (BAO‐TNK)

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To compare the effectiveness and safety of tenecteplase (TNK) versus alteplase (TPA) in patients with basilar artery occlusion prior to endovascular treatment (EVT). Methods In this retrospective multicenter study (BAO‐TNK), we analyzed consecutive BAO patients from 14 U.S.
Rahul R. Karamchandani   +38 more
wiley   +1 more source

Triple Negative Breast Cancer Patients Treated with Radiation Therapy: Improvement in Survival and Local Control With Adjuvant Chemotherapy Compared To Neoadjuvant Chemotherapy – A Hypothesis Generating Report [PDF]

open access: green, 2021
Mary R Nittala   +14 more
openalex   +1 more source

Will Memantine Exacerbate Seizures in People With Epilepsy? A Prospective Cohort Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate whether add‐on memantine would exacerbate seizures in people with epilepsy. Methods This was a prospective cohort study. People with epilepsy diagnosed with cognitive impairment were consecutively invited. Those who agreed were followed up for at least 24 weeks.
Peiyu Wang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy